|
Clippings
Theme: Pediatric Endrocrinology
|
Aashima Dabas
Email:
[email protected]
|
|
Air pollution predisposes to adverse metabolic profile in children
(Pediatr Obes. 2018;13:54-62)
|
With increasing globalization, there are increasing concerns of air
pollution on human health. The effect of pollutants (nitric oxide,
particulate matter and traffic-related pollutants) were assessed in 429
overweight and obese African-American youth living in California. Air
pollutants were associated with higher fasting insulin, lower insulin
sensitivity and higher fasting glucose (P<0.05). The authors
concluded a higher risk of type-2 diabetes among overweight and obese
children exposed to air pollution.
|
|
ACE inhibitors and statins in type-1 diabetes (N Engl
J Med. 2017;377:1733-45)
|
Adolescents with type-1 Diabetes may develop microalbuminuria, which
predisposes them to future cardiovascular and renal morbidity. In this
placebo controlled trial, 443 adolescents with type-1 Diabetes were
randomized to receive ACE inhibitors and/or statins, and monitored 6
monthly over next 2-4 years. The albumin:creatinine excretion remained
unaffected with ACE inhibitors, statins or combination therapy. The
lipid profile improved in the group receiving statins; however, there
was no difference noted in carotid intima-media thickness, other
cardiovascular markers, glomerular filtration rate, or progression of
retinopathy between groups. The use of these drugs in type 1 Diabetes
was not found to be beneficial for most functional outcomes.
|
|
Metformin in type-1 diabetes (J Clin Endocrinol Metab.
2017;102:4448-56)
|
Metformin has been shown to have a protective effect on cardiovascular
morbidity in type-2 diabetes. The evidence for its use is less robust
among patients with type-1 diabetes. Ninety children (age 8-18 years)
with type-1 diabetes and BMI >50th centile were randomly assigned to
receive metformin (1 g twice daily) or placebo for twelve months in this
trial. The use of metformin was associated with significant improvement
in glyceryl trinitrate-mediated dilatation of brachial artery (by 3.3%
units), reduction in insulin dose (0.2 U/kg/d) and reduction in glycated
hemoglobin (1%). The carotid/aortic intima media thickness, BMI, lipids,
blood pressure and other cardiovascular risk factors were similar
between both groups. Patients reported higher incidence of
gastrointestinal side effects with metformin use. The authors concluded
further consideration before use of metformin in type-1 diabetes.
|
|
Prediction of spontaneous puberty in Turner syndrome (Horm
Res Pediatr. 2017;doi: 10.1159/000485321. [Epub ahead of
print])
|
Spontaneous onset and normal progression of puberty is known to occur in
a subset of girls with Turner syndrome, usually am ong mosaics and less
frequently among those with 45, X. This study evaluated 110 girls (mean
age 10.7 years) with Turner syndrome over a 20 year period (mean
follow-up 5.9 years). Their gonadotropins, karyotype and ovarian sizes
were recorded during follow-up. Spontaneous puberty (thelarche) and
menarche were noted in 48% and 20% girls, respectively, with lesser
proportion among those with 45,X. Ovarian size showed poor correlation
with prediction of spontaneous puberty. A cut off of FSH >6.7 IU/L
between 6-10 years was associated with higher probability of delayed
menarche. The authors precluded the role of karyotype alone in
predicting spontaneous puberty in Turner syndrome.
|
|
Growth outcomes with early therapy in X-linked
hypophosphatemic rickets (Pediatr ENdocrinol Rev.
2017;15:119-21)
|
X-linked hypophosphatemic rickets (XLH) is a cause of refractory rickets
which affects can predispose to growth abnormalities and skeletal
deformities. This paper reported the growth patterns of 127 participants
with XLH across 49 centers. All had normal length at birth. Height
decelerated till mean age of 4.3 years (height SDS -3.2) to ultimately
show catch-up by +1.3 height SDS until onset of puberty. Among 10/18
children treated with calcitriol and phosphate before 18 months of age,
the height SDS improved from -2.2 at 4.4 yr to -1.4 around puberty to
achieve adult height SDS of -2.4. Early treatment was shown to improve
growth rate in these children.
|
|
Liraglutide for reducing cardiovascular risk
in polycystic overy syndrome (Endocr Connect. 2018;115-21)
|
Liraglutide is a glucagon-like pepetide 1 that is used in type-2
diabetes. Authors investigated its role in 72 overweight women with
polycystic ovary syndrome in a placebo controlled trial where
liraglutide was given at 1.8 mg/day for 26 weeks. Cardiac biomarkers
like atrial natriuretic peptide (ANP), adrenomedullin (ADM), copeptin
and insulin resistance were estimated. Significant reduction in ANP
(25%) and ADM (6%), unlike copeptin, were noted in the intervention
group. A reduction in ANP significantly correlated with an increase in
heart rate on regression analysis.
|
|
Growth hormone in Juvenile idiopathic arthritis (J
Clin Endocrinol Metab. 2017;102:4578-87)
|
Growth hormone has been found safe and beneficial in juvenile idiopathic
arthritis (JIA). Growth outcomes of 53 patients with JIA receiving long
term corticosteroids were analyzed after GH therapy for a median
duration 6.5 years. Height SD scores improved from -2.9 at baseline to
-1.7 in adulthood with corrected height SD score at -1.3 (IQR, -3.0 to
-0.2) after therapy. Earlier age of Growth hormone initiation, higher
height at initiation and lesser disease inflammation during follow-up
(lower serum C-reactive levels) improved height outcomes independently.
|